Fig. 2From: Lung transplant referral practice patterns: a survey of cystic fibrosis physicians and general pulmonologistsReferral Influencers: the potential impact of (a) current CFTR-modulator therapy, and (b) anticipated therapy with a highly effective CFTR modulator (i.e. triple-combination CFTR modulator or other promising new therapy) on the timing of CF providers’ referral for lung transplant evaluation, and the potential impact of (c) an anticipated promising new therapy targeting underlying disease process on the referral timing of non-CF pulmonary providers. Panels show the proportion of responding providers who would not change or potentially delay the timing of their referral based on these factorsBack to article page